Carbapenem Resistance

If you later develop a serious bacterial infection, a known history of resistant gut carriage can help your care team choose initial antibiotics. It also helps hospitals limit transmission. A positive stool DNA result needs to be interpreted alongside the gene detected, your healthcare exposure, and your symptoms.

What This Stool Test Measures

Carbapenems are antibiotics used for serious bacterial infections, including some caused by organisms resistant to other drugs. Carbapenemases are bacterial enzymes that break down these antibiotics. Some bacteria resist carbapenems through other mechanisms.

This test uses qPCR to look for bacterial resistance DNA in stool. qPCR amplifies selected DNA sequences and detects them during that process. It can support either a detected/not-detected report or a quantitative report, depending on the assay. The available information for this test does not specify its gene targets, reporting format, or a unit.

Common hospital assays target KPC, NDM, VIM, IMP, and OXA-48-like carbapenemase gene families. That list cannot be assumed to describe this test. Published performance figures for Xpert Carba-R also cannot be assigned to an unspecified stool qPCR assay. Much of that research used rectal swabs, which require their own specimen validation.

Carbapenemase genes occur in bacteria including Klebsiella pneumoniae and Escherichia coli. Many can travel between bacteria on plasmids. Plasmids are small DNA molecules that can carry genes between bacterial cells. Finding a resistance gene and a bacterial species in the same stool sample does not establish that the species carries the gene.

Where Screening Has an Established Role

Validated screening for carbapenemase-producing organisms is established in hospital infection prevention, particularly during outbreaks and after relevant healthcare exposures. Its usefulness depends on the setting and on whether the result will change infection-control or treatment decisions. Routine screening of otherwise healthy people, or using stool gene quantities to guide longevity care, has not been shown to improve health outcomes.

Colonization and Infection

Colonization means carrying bacteria without an infection caused by them. A positive resistance-gene result can suggest intestinal carriage, but DNA detection alone does not prove that living resistant organisms are present. A well person does not need antibiotics solely because this screening result is positive.

The chance of later infection depends on your circumstances. Intensive care, impaired immune defenses, damage to the bowel lining, and invasive devices can increase vulnerability. Central lines and urinary catheters can provide entry points for bacteria.

What Hospital Studies Show

In one intensive-care cohort, 47% of people with carbapenem-resistant Enterobacterales detected by rectal-swab culture developed an infection with these organisms within 30 days. Colonization remained strongly associated with infection after adjustment for other factors. This study measured cultured resistant organisms and involved seriously ill people; it does not give a personal risk estimate for a healthy person with a positive stool DNA result.

Another hospital study used rectal-swab PCR together with culture. Among intensive-care and oncology or hematology inpatients, acquiring carriage during admission was associated with about eight times the rate of a resistant bloodstream infection in the adjusted analysis. That supports surveillance in these settings, but it does not establish the predictive accuracy of this stool assay.

Pediatric cancer research also links intestinal carriage of resistant bacteria with later bloodstream infection and bowel complications. The cited study used stool cultures and included several resistance patterns. Its infection figures cannot be treated as the risk from detecting a carbapenemase gene alone.

Why Infection With a Resistant Organism Matters

A meta-analysis of hospitalized adults with serious Enterobacterales infections found roughly three times the odds of death with carbapenem-resistant organisms compared with susceptible organisms. These were outcomes of established infections, not outcomes predicted from a positive stool screening result.

In the prospective PANORAMA study across ten countries, in-hospital mortality was 35% among people with resistant bloodstream infections and 20% among those with susceptible bloodstream infections. An association remained after adjustment for measured differences between the groups. Underlying illness and access to effective treatment also affect outcomes; these percentages are not the mortality risk of intestinal carriage.

The size of the association varies. One study of Klebsiella pneumoniae bloodstream infections found no statistically clear mortality difference after balancing patient and disease factors. Resistance can restrict treatment options, while the severity of the infection and your underlying health remain central to the outcome.

Can the Amount Predict Infection?

A pediatric study used research qPCR on rectal swabs to estimate resistance-gene abundance relative to total bacterial DNA. Higher relative abundance of blaOXA-48 was associated with finding organisms carrying that gene outside the intestine. Some samples were collected before those episodes, some on the same day, and some afterward. This does not establish a validated forecasting tool or a treatment target for this stool test.

When Results Can Be Misleading

A positive qPCR result identifies a DNA target. It cannot establish the organism's viability, identify which species carries the gene, show how actively the gene is expressed, or provide a full antibiotic susceptibility profile. Culture can recover living bacteria for identification and drug testing, although low-density carriage or the culture method can prevent recovery.

In a study of 2,861 rectal swabs using a hospital molecular screening protocol, culture recovered no corresponding organism from about a quarter of molecular-positive specimens. PCR and culture answer different questions, and disagreement needs interpretation using both methods' limitations.

A negative result means the targeted DNA was not detected in that specimen. Genes outside the assay's coverage and variants it cannot recognize will be missed. Other routes to resistance include reduced antibiotic entry combined with other antibiotic-destroying enzymes, and increased removal of the drug from bacterial cells.

Low amounts of target DNA, inadequate sampling, transport problems, and substances that interfere with DNA amplification can cause missed detections or invalid results. Recent antibiotics can change which organisms are present and how readily they are detected. An invalid result is not a negative result.

Serial Results

Intestinal carriage can persist for months, and detection can fluctuate. A later negative does not establish permanent clearance. If a report gives only detected/not detected, there is no numeric level to trend. Quantities from different methods, gene panels, or laboratories should not be treated as interchangeable, and a falling DNA signal has no established meaning as a reduction in your infection risk.